This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Healthcare ETFs on Radar As Q1 Earnings Unfold
by Sweta Killa
Further price movement of the healthcare ETFs depend on earnings releases from some big names like Pfizer (PFE), Merck (MRK), Thermo Fisher (TMO), AbbVie (ABBV), and Gilead Sciences (GILD) that dominate returns.
Healthcare ETFs in Focus Post JNJ's Q1 Earnings Results
by Sweta Killa
Johnson & Johnson (JNJ) continued its long streak of earnings beat and outpaced revenue estimates. However, the company tightened its full-year guidance.
Healthcare ETFs to Gain on UnitedHealth's Strong Q1 Earnings
by Sweta Killa
UnitedHealth Group (UNH) reported better-than-expected first-quarter 2021 results wherein it breezed past the Zacks Consensus Estimate on both earnings and revenues. It also lifted its full-year earnings outlook.
Will J&J ETFs Suffer on Latest COVID-19 Vaccine Updates?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs that can see adverse impacts as Johnson & Johnson's coronavirus vaccine sees a setback amid the worsening pandemic conditions.
J&J ETFs to Shine Bright as FDA Grants EUA for Coronavirus Vaccine
by Sweta Jaiswal, FRM
Johnson & Johnson's receipt of EUA for its single-shot COVID-19 vaccine will strengthen the U.S. government's position in the fight against the pandemic and benefit ETFs with high exposure to the pharmaceutical giant.
JNJ Touches New Highs Post Solid Q4 Earnings: ETFs in Focus
by Sweta Killa
The solid results coupled with upbeat vaccine data optimism pushed JNJ shares to all-time high.
Healthcare ETFs in Focus on UnitedHealth's Solid Q4 Earnings
by Sweta Killa
UnitedHealth Group (UNH) reported better-than-expected fourth-quarter 2020 results wherein it breezed past the Zacks Consensus Estimate on both earnings and revenues.
ETFs to Gain on UnitedHealth and Change Healthcare Deal
by Sweta Killa
UnitedHealth agreed to buy Change Healthcare for $7.84 billion in cash.
Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus
by Sweta Killa
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus
by Sweta Killa
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
UnitedHealth Q3 Solid Result Put Healthcare ETFs in Focus
by Sweta Killa
UnitedHealth reported better-than-expected third-quarter 2020 results wherein it breezed past the Zacks Consensus Estimate on both earnings and revenues. It also lifted its full year outlook.
J&J Pauses Coronavirus Vaccine Trial: ETFs That May Take a Hit
by Sweta Jaiswal, FRM
Johnson & Johnson's pausing of dosing in all clinical studies on its coronavirus vaccine candidate has increased uncertainty surrounding the coronavirus vaccine development.
JNJ Beats Q3 Earnings, Lifts Outlook: Healthcare ETFs in Focus
by Sweta Killa
Despite solid results and an upbeat view, shares of JNJ dropped as the company halted its final-phase of clinical trials for its COVID-19 vaccine candidate.
4 Top ETFs, Stocks From Attractive Sectors Pre Q3 Earnings
by Sweta Killa
We have highlighted one ETF and one stock from the four sectors that could make great plays as the earnings season unfolds.
Bet on Defensive Sector ETFs as Stimulus Talks Stall
by Sweta Killa
The halt in stimulus talks has made investors jittery, resulting in a flight to defensive sectors like utilities, real estate, healthcare and consumer staples.
Trump vs. Biden First Presidential Debate: ETFs in Focus
by Sweta Killa
After months of campaign, President Donald Trump and Democratic nominee Joe Biden will come face-to-face on debate stage on Sep 30 in Cleveland.
ETFs in Focus on Momenta Buyout Deal With JNJ
by Sweta Killa
A number of ETFs could be the best ways for investors to tap the opportunity arising from the Momenta buyout deal.
What Lies Ahead for Healthcare ETFs in Q2 Earnings?
by Sweta Killa
The healthcare sector is expected to witness substantial earnings decline of 6.9% in the second quarter, representing the second strongest sector this earnings season.
UnitedHealth Beats: Healthcare ETFs in Focus
by Sweta Killa
UnitedHealth Group reported stronger-than-expected second-quarter 2020 results wherein it breezed past the Zacks Consensus Estimate on both earnings and revenues.
Q2 Earnings Likely To Plunge: Invest in These Sector ETFs
by Sweta Killa
Earnings growth is expected to be negative for 15 of the 16 Zacks sectors with double-digit declines.
Healthcare ETFs Looks Strong Ahead of Q1 Earnings
by Sweta Killa
The healthcare sector has been on a tear driven by potential vaccines and treatments for COVID-19.
Healthcare ETFs to Gain on Progress in COVID-19 Antibody Tests
by Sweta Jaiswal, FRM
Along with molecular testing, antibody testing is gaining immense prominence as economies are struggling to reopen.
Healthcare ETFs in Focus Post UnitedHealth's Q1 Earnings
by Sweta Killa
UnitedHealth reported mixed first-quarter 2020 results wherein it breezed past the Zacks Consensus Estimate on earnings but lagged the same for revenues.
JNJ Beats, Cuts View on Coronavirus: Healthcare ETFs in Focus
by Sweta Killa
Investors should closely watch the movement of the stock and keep a close eye on ETFs having double-digit allocation to this diversified drug maker post its earnings release.
Any Bright Spot in Q1 Earnings? Sector ETFs & Stocks to Buy
by Sweta Killa
First-quarter results are likely to be bleak, given that the coronavirus outbreak are weighing on corporate profits. However, there are still some bright spots. Let's have a look.